Physician profile
Katie M Ho
NPI 1700405677
$1,685.53
in general payments reported to CMS, 2019-2025
16 companies · $37.26 in 2025
The $37.26 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,648 · 2025: $37.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.79 | 2021 | |
| Intuitive Surgical, INC. | $250.00 | 2021 | |
| Csl Behring | $169.14 | 2021 | |
| Glaxosmithkline, LLC. | $150.59 | 2021 | |
| Genzyme Corporation | $134.84 | 2021 | |
| Kaleo, INC. | $102.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.73 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $87.31 | 2021 | |
| Pfizer INC. | $86.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.11 | 2021 | |
| Merz North America, INC. | $37.26 | 2025 | |
| Eyevance Pharmaceuticals LLC | $32.50 | 2021 | |
| Grifols USA, LLC | $22.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.42 | 2021 | |
| Biocryst US Sales Co., LLC | $19.27 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.